Newborn Metabolic Screening Market to US$ 857.4 Million by 2034

According to estimates, the Newborn Metabolic Screening Market will be valued US$ 355.1 million by 2024. With a predicted growth rate of 9.2% between 2024 and 2034, the need for newborn metabolic screening is expected to rise in a positive manner. By 2034, the market is expected to be worth more than US$ 857.4 million. the market is growing mainly because parents and healthcare professionals are becoming more aware of how important it is to identify metabolic problems early on. There has been a noticeable increase in demand for improved screening technologies and approaches as routine screening becomes common practice. Furthermore, as more cases are diagnosed and the global healthcare infrastructure keeps growing, proactive newborn screening is becoming increasingly prevalent.

Get Free Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=6323

The integration of innovative technologies is a notable trend shaping the newborn metabolic screening market. The development of mass spectrometry and genetic testing technologies has given medical professionals strong instruments to identify many kinds of abnormalities in newborns early in their lives. The advent of next-generation sequencing and other high-throughput techniques has revolutionized the precision and efficiency of screening processes.

The global push by healthcare authorities for universal newborn screening programs has created a conducive environment for market growth. Governments and health agencies are recognizing the long-term benefits of early detection. This is prompting increased investments in screening programs and infrastructure. By focusing on early intervention and preventative measures, this combined endeavor seeks to lessen the burden of metabolic illnesses on individuals and healthcare systems. Additionally, the increasing emphasis on personalized medicine presents a unique opportunity for the market.

Regional Outlook:

From 2024 to 2034, North America is expected to see a promising increase in revenue for newborn metabolic screening. The primary force driving the market beyond is the growing incidence of congenital diseases, especially in the United States. In the country, for example, an infant with a congenital disability comes into existence every four and half minutes, according to the Centers for Disease Control and Prevention. The newborn screening program has been strictly adhered to in all of North America's states due to the crucial conditions that have developed throughout time, encouraging market expansion.

In the next ten years, East Asia's newborn metabolic screening market is expected to grow steadily, showing a modest CAGR of 9.6%. Increased disposable income, better healthcare facilities, and the region's high fertility rates all encourage market expansion. China and India possessed fertility rates of 1.8 and 2.2 in 2020, respectively. Furthermore, government programs, rising healthcare costs, and a greater understanding of the benefits of newborn screening throughout the region are anticipated to propel the market positively in East Asia.

Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=6323

"The market is expected to surge rapidly with the introduction of revolutionary DNA sequencing technology. Gene panels with greater scope are projected to improve early identification and treatment for multiple conditions. Moreover, machine learning is likely to transform newborn metabolic screening by effectively evaluating large amounts of data, offering profitable prospects for newborn metabolic screening market growth." says a Fact.MR analyst.

Key Companies Profiled in This Report:

PerkinElmer
Bio-Rad Laboratories
Trivitron Healthcare Private Limited
BioMedomics, Inc.
Luminex Corporation
MP BIOMEDICALS
Synergy Medical Systems LLP
Agilent Technologies, Inc.
Thermo Fisher Scientific, Inc.
Zivak Technologies
Covidien Plc
AB Sciex LLC
Waters Corp.
Masimo Corp.
Natus Medical Inc.

Key Takeaways from the Market Study:

The global newborn metabolic screening market is projected to expand at a CAGR of 9.2% through 2034.

The North America newborn metabolic screening industry is expected to develop at a promising CAGR of 9.4% through 2034.

The United States dominates the global newborn metabolic screening market, estimated to value at US$ 87 million in 2024. The market is likely to surge at a CAGR of 9.8% through 2034.

The newborn metabolic screening industry in China is expected to rise at a CAGR of 9.9%, reaching a valuation of US$ 70 million by 2034.

Based on test type, sickle cell disease is likely to hold a 32.5% market share in 2024.

The hospital segment is set to dominate the end-user category with a 40.3% share in 2024.

Browse Full Report @ https://www.factmr.com/report/newborn-metabolic-screening-market

Competitive Landscape

Leading market players focus on enhancing test accuracy and expanding test panels while startups innovate with cost-effective solutions and rapid results. Established firms prioritize strategic partnerships for broader market penetration, while newcomers leverage niche expertise and agility to carve out specialized segments, fostering healthy competition.

The EONIS screening test, which is utilized to screen infants for XLA (X-linked agammaglobulinemia), SCID (severe combined immunodeficiency), and SMA (spinal muscular atrophy), was approved by CE-IVD in September 2020 for PerkinElmer.

In January 2023, Masimo unveiled its state-of-the-art infant monitoring device. This was designed to empower caregivers to monitor baby data in real-time.

Explore More Related Studies Published by Fact.MR Research:

Medical Ceramics Market
https://www.factmr.com/report/medical-ceramics-market

Thoracic Drainage Devices Market
https://www.factmr.com/report/thoracic-drainage-devices-market

Patient Temperature Monitoring Market
https://www.factmr.com/report/patient-temperature-monitoring-market

Cochlear Implant Market
https://www.factmr.com/report/cochlear-implant-market

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:
US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.